144 related articles for article (PubMed ID: 38561023)
1. Targeting CD33+ acute myeloid leukemia with GLK-33, a lintuzumab-auristatin conjugate with a wide therapeutic window.
Satomaa T; Pynnönen H; Aitio O; Hiltunen JO; Pitkänen V; Lähteenmäki T; Kotiranta T; Heiskanen A; Hänninen AL; Niemelä R; Helin J; Kuusanmaki H; Vänttinen I; Rathod R; Nieminen AI; Yatkin E; Heckman CA; Kontro M; Saarinen J
Mol Cancer Ther; 2024 Apr; ():. PubMed ID: 38561023
[TBL] [Abstract][Full Text] [Related]
2. Development of Highly Optimized Antibody-Drug Conjugates against CD33 and CD123 for Acute Myeloid Leukemia.
Han YC; Kahler J; Piché-Nicholas N; Hu W; Thibault S; Jiang F; Leal M; Katragadda M; Maderna A; Dushin R; Prashad N; Charati MB; Clark T; Tumey LN; Tan X; Giannakou A; Rosfjord E; Gerber HP; Tchistiakova L; Loganzo F; O'Donnell CJ; Sapra P
Clin Cancer Res; 2021 Jan; 27(2):622-631. PubMed ID: 33148666
[TBL] [Abstract][Full Text] [Related]
3. LILRB4-targeting Antibody-Drug Conjugates for the Treatment of Acute Myeloid Leukemia.
Anami Y; Deng M; Gui X; Yamaguchi A; Yamazaki CM; Zhang N; Zhang CC; An Z; Tsuchikama K
Mol Cancer Ther; 2020 Nov; 19(11):2330-2339. PubMed ID: 32879051
[TBL] [Abstract][Full Text] [Related]
4. CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells.
Liu Y; Wang S; Schubert ML; Lauk A; Yao H; Blank MF; Cui C; Janssen M; Schmidt C; Göllner S; Kleist C; Zhou F; Rahfeld JU; Sauer T; Schmitt M; Müller-Tidow C
Int J Cancer; 2022 Apr; 150(7):1141-1155. PubMed ID: 34766343
[TBL] [Abstract][Full Text] [Related]
5. IMGN779, a Novel CD33-Targeting Antibody-Drug Conjugate with DNA-Alkylating Activity, Exhibits Potent Antitumor Activity in Models of AML.
Kovtun Y; Noordhuis P; Whiteman KR; Watkins K; Jones GE; Harvey L; Lai KC; Portwood S; Adams S; Sloss CM; Schuurhuis GJ; Ossenkoppele G; Wang ES; Pinkas J
Mol Cancer Ther; 2018 Jun; 17(6):1271-1279. PubMed ID: 29588393
[TBL] [Abstract][Full Text] [Related]
6. Gemtuzumab ozogamicin and novel antibody-drug conjugates in clinical trials for acute myeloid leukemia.
Yu B; Liu D
Biomark Res; 2019; 7():24. PubMed ID: 31695916
[TBL] [Abstract][Full Text] [Related]
7. De Novo design of a humanized antiCD33 antibody-oridonin conjugate for acute myeloid leukemia therapy.
Feng H; Liu Y; Zhang M; Liu R; Wang J; Wang W; He P; Zhang P; Niu F
Biochem Biophys Res Commun; 2022 Nov; 629():152-158. PubMed ID: 36122452
[TBL] [Abstract][Full Text] [Related]
8. Investigational CD33-targeted therapeutics for acute myeloid leukemia.
Walter RB
Expert Opin Investig Drugs; 2018 Apr; 27(4):339-348. PubMed ID: 29534618
[TBL] [Abstract][Full Text] [Related]
9. Antibody-Drug Conjugates for the Treatment of Acute Pediatric Leukemia.
Stokke JL; Bhojwani D
J Clin Med; 2021 Aug; 10(16):. PubMed ID: 34441852
[TBL] [Abstract][Full Text] [Related]
10. FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia.
Norsworthy KJ; Ko CW; Lee JE; Liu J; John CS; Przepiorka D; Farrell AT; Pazdur R
Oncologist; 2018 Sep; 23(9):1103-1108. PubMed ID: 29650683
[TBL] [Abstract][Full Text] [Related]
11. Anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia.
Sutherland MK; Yu C; Lewis TS; Miyamoto JB; Morris-Tilden CA; Jonas M; Sutherland J; Nesterova A; Gerber HP; Sievers EL; Grewal IS; Law CL
MAbs; 2009; 1(5):481-90. PubMed ID: 20065652
[TBL] [Abstract][Full Text] [Related]
12. Trastuzumab-MMAU Antibody-Auristatin Conjugates: Valine-Glucoserine Linker with Stabilized Maleimide Conjugation Improves In Vivo Efficacy and Tolerability.
Goldberg SD; Satomaa T; Aina O; Aitio O; Burke K; Dudkin V; Geist B; Irrechukwu O; Hänninen AL; Heiskanen A; Helin J; Hiltunen JO; Kinyamu-Akunda J; Klein DM; Kohli N; Kotiranta T; Lähteenmäki T; Niemelä R; Pitkänen V; Pynnönen H; Rittase W; Wiley K; Zhou J; Saarinen J
Mol Cancer Ther; 2024 Feb; ():. PubMed ID: 38324296
[TBL] [Abstract][Full Text] [Related]
13. What happened to anti-CD33 therapy for acute myeloid leukemia?
Jurcic JG
Curr Hematol Malig Rep; 2012 Mar; 7(1):65-73. PubMed ID: 22109628
[TBL] [Abstract][Full Text] [Related]
14. SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML.
Kung Sutherland MS; Walter RB; Jeffrey SC; Burke PJ; Yu C; Kostner H; Stone I; Ryan MC; Sussman D; Lyon RP; Zeng W; Harrington KH; Klussman K; Westendorf L; Meyer D; Bernstein ID; Senter PD; Benjamin DR; Drachman JG; McEarchern JA
Blood; 2013 Aug; 122(8):1455-63. PubMed ID: 23770776
[TBL] [Abstract][Full Text] [Related]
15. Gemtuzumab ozogamicin in acute myeloid leukemia.
Godwin CD; Gale RP; Walter RB
Leukemia; 2017 Sep; 31(9):1855-1868. PubMed ID: 28607471
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxic activity of gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia correlates with the expression of protein kinase Syk.
Balaian L; Ball ED
Leukemia; 2006 Dec; 20(12):2093-101. PubMed ID: 17051243
[TBL] [Abstract][Full Text] [Related]
17. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
[TBL] [Abstract][Full Text] [Related]
18. A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability.
ten Cate B; Bremer E; de Bruyn M; Bijma T; Samplonius D; Schwemmlein M; Huls G; Fey G; Helfrich W
Leukemia; 2009 Aug; 23(8):1389-97. PubMed ID: 19262596
[TBL] [Abstract][Full Text] [Related]
19. 225Ac-labeled CD33-targeting antibody reverses resistance to Bcl-2 inhibitor venetoclax in acute myeloid leukemia models.
Garg R; Allen KJH; Dawicki W; Geoghegan EM; Ludwig DL; Dadachova E
Cancer Med; 2021 Feb; 10(3):1128-1140. PubMed ID: 33347715
[TBL] [Abstract][Full Text] [Related]
20. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells.
van Der Velden VH; te Marvelde JG; Hoogeveen PG; Bernstein ID; Houtsmuller AB; Berger MS; van Dongen JJ
Blood; 2001 May; 97(10):3197-204. PubMed ID: 11342449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
